Table 4 General characteristics of patients with HER2-negative breast cancer in prognostic analysis cohort
|  | Total numbers (n = 132) | Disease-free numbers (n = 116) | Disease-progressive numbers (n = 16) |
|---|---|---|---|
Age, years (± SD) | |||
 < 50 | 51 (38.6) | 43 (37.1) | 8 (50.0) |
 ≥ 50 | 81 (61.4) | 73 (62.9) | 8 (50.0) |
BMI‡ | |||
 < 25 | 85 (64.4) | 76 (65.5) | 9 (56.3) |
 ≥ 25 | 47 (35.6) | 40 (34.5) | 7 (43.7) |
T stage | |||
 1/2 | 117 (88.6) | 104 (89.7) | 13 (81.3) |
 3/4 | 15 (11.4) | 12 (10.3) | 3 (18.7) |
Lymphatic metastasis | |||
 Absent | 42 (31.8) | 39 (33.6) | 3 (18.8) |
 Present | 90 (68.2) | 77 (66.4) | 13 (81.2) |
Histologic grade | |||
 Grade I/ II | 67 (50.8) | 60 (51.7) | 7 (43.8) |
 Grade III | 65 (49.2) | 56 (48.3) | 9 (56.2) |
Tumor histology | |||
 Ductal | 111 (84.1) | 97 (83.6) | 14 (87.5) |
 Non-ductal | 21 (15.9) | 19 (16.4) | 2 (12.5) |
ER | |||
 Negative | 39 (29.5) | 31 (26.7) | 8 (50.0) |
 Positive | 93 (70.5) | 85 (73.3) | 8 (50.0) |
PR | |||
 Negative | 51 (38.6) | 42 (36.2) | 9 (56.2) |
 Positive | 81 (61.4) | 74 (63.8) | 7 (43.8) |
HER2 | |||
 Zero | 50 (37.9) | 42 (36.2) | 8 (50.0) |
 Low | 82 (62.1) | 74 (63.8) | 8 (50.0) |
Ki-67 | |||
 < 30% | 42 (31.8) | 38 (32.8) | 4 (25.0) |
 ≥ 30% | 90 (68.2) | 78 (67.2) | 12 (75.0) |
Molecular types | |||
 Luminal | 93 (70.5) | 85 (73.3) | 8 (50.0) |
 Triple-negative | 39 (29.5) | 31 (26.7) | 8 (50.0) |
Treatment | |||
 NAT | 72 (54.5) | 62 (53.4) | 10 (62.5) |
 Non-NAT | 60 (45.5) | 54 (46.6) | 6 (37.5) |
SUVmax |  | 5.69 (3.58–9.04) | 7.97 (4.16–16.05) |
MTV |  | 7.01 (4.10–12.38) | 13.82 (4.40–22.05) |
TLG |  | 24.62 (10.56–45.14) | 35.87 (16.32–209.96) |
TLR |  | 2.36 (1.46–3.68) | 2.74 (1.63–5.97) |